Who
Joseph C. Scodari
Director
Company insider
Files Form 4 as: Director, Acurx Pharmaceuticals; Director, OptiNose; Director, Covance; Director, Endo Health Solutions; Executive Committee Member, Johnson & Johnson.
In numbers
- Trades disclosed
- 131
- Buys
- 9
- Sells
- 2
- Bought
- $360K
- Sold
- $8.2M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 31 Jan 2006
- Last trade
- 20 Apr 2026
- Last filed
- 22 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Apr 2026filed 22 Apr 2026 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,150 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,150 at $0.00 | filing |
| 6 Jan 2025filed 8 Jan 2025 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —24,631 at $0.00 | filing |
| 6 Jan 2025filed 8 Jan 2025 | ACXP Acurx PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K24,631 at $1.02 | filing |
| 17 Jun 2024filed 18 Jun 2024 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | OptiNoseoption or derivative | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 1 Jul 2021filed 6 Jul 2021 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Jun 2021filed 10 Jun 2021 | OptiNoseoption or derivative | SEC FORM 4 Code A | —14,439 at $0.00 | filing |
| 10 May 2021filed 11 May 2021 | OptiNose | SEC FORM 4 Bought | $30K10,000 at $2.99 | filing |
| 10 Jun 2020filed 12 Jun 2020 | OptiNoseoption or derivative | SEC FORM 4 Code A | $82K14,439 at $5.65 | filing |
| 6 Mar 2020filed 9 Mar 2020 | OptiNose | SEC FORM 4 Bought | $37K6,500 at $5.75 | filing |
| 6 Mar 2020filed 9 Mar 2020 | OptiNose | SEC FORM 4 Bought | $11K2,000 at $5.56 | filing |
| 6 Mar 2020filed 9 Mar 2020 | OptiNose | SEC FORM 4 Bought | $1,106200 at $5.53 | filing |
| 6 Dec 2019filed 9 Dec 2019 | OptiNose | SEC FORM 4 Bought | $50K6,100 at $8.22 | filing |
| 6 Jun 2019filed 10 Jun 2019 | OptiNoseoption or derivative | SEC FORM 4 Code A | $95K14,439 at $6.60 | filing |
| 12 Dec 2018filed 12 Dec 2018 | OptiNose | SEC FORM 4 Bought | $51K6,430 at $7.89 | filing |
| 11 Jun 2018filed 11 Jun 2018 | OptiNoseoption or derivative | SEC FORM 4 Code A | $325K14,439 at $22.50 | filing |
| 12 Oct 2017filed 16 Oct 2017 | OptiNoseoption or derivative | SEC FORM 4 Code A | —43,318 at $0.00 | filing |
| 19 Feb 2015filed 23 Feb 2015 | Covance | SEC FORM 4 Code D | —7,466 | filing |
News
Capital Group Core Balanced ETF (NYSE: CGBL) Opens New Position In Johnson & Johnson (NYSE: JNJ)JNJ · foreignpolicyjournal.com · 23 Oct 2026Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026JNJ · finanznachrichten.de · 22 Oct 2026Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Climb 0.9% – Should You Buy?ACXP · dailypolitical.com · 22 Oct 2026Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?JNJ · aol.com · 21 Oct 2026
0 headlines in the last 90 days name Joseph C. Scodari; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.